Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session – BOTHELL, WA,, April 15, 2020 (GLOBE NEWSWIRE) -- Cocrystal...
March 30, 2020 06:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
March 11, 2020 09:40 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, March 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
March 09, 2020 15:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, March 09, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
March 06, 2020 16:01 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Plans to Advance Coronavirus Program

Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s...
February 28, 2020 14:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
February 27, 2020 07:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
February 24, 2020 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds

BOTHELL, WA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used to...
February 13, 2020 08:30 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of Antivirals

– Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address additional viral diseases,...
February 11, 2020 08:35 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference

– Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage...